Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study

Clinical trial NCT02100618 · WITHDRAWN

Trial details

NCT number: NCT02100618
Sponsor: GlaxoSmithKline
Status: WITHDRAWN
Phase: Phase 3
Study type: INTERVENTIONAL

Infections, Papillomavirus

Start date: 2015-01-01
Primary completion: 2015-04-01
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.